Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

Cancer Letters

Volumn 303, Issue 1, 2011, Pages 21-28

  Zhang, Youwei ^a   Wang, Rui ^a   Song, Haizhu ^a   Huang, Guichun ^a   Yi, Jun ^b   Zheng, Yun ^a   Wang, Jinghua ^a   Chen, Longbang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Biomarker; CIMP; Circulating DNA; Methylation; Non small cell lung cancer

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; FRAGILE HISTIDINE TRIAD PROTEIN; LIMBIC SYSTEM ASSOCIATED MEMBRANE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSCRIPTION FACTOR RUNX3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CDH13 GENE; CHINESE; CMTM3 GENE; CONTROLLED STUDY; CPG ISLAND; DLEC GENE; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; KLK10 GENE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OPCML GENE; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 79951850937     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.12.011     Document Type: Article

References (42)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59:225-249.
2. Risch A., Plass C. Lung cancer epigenetics and genetics. Int J. Cancer 2008, 123:1-7.
3. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
4. Zou X.P., Zhang B., Zhang X.Q., Chen M., Cao J., Liu W.J. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum. Pathol. 2009, 40:1534-1542.
5. Duffy M.J., Napieralski R., Martens J.W., Span P.N., Spyratos F., Sweep F.C., Brunner N., Foekens J.A., Schmitt M. Methylated genes as new cancer biomarkers. Eur. J. Cancer 2009, 45:335-346.
6. Anglim P.P., Alonzo T.A., Laird-Offringa I.A. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol. Cancer 2008, 7:81.
7. Heller G., Zielinski C.C., Zöchbauer-Müller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 2010, 29:95-107.
8. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., Glöckner S., Piantadosi S., Gabrielson E., Pridham G., Pelosky K., Belinsky S.A., Yang S.C., Baylin S.B., Herman J.G. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 2008, 358:1118-1128.
9. Feng Q., Hawe S.E., Stern J.E., Wiens L., Lu H., Dong Z.M., Jordan C.D., Kiviat N.B., Vesselle H. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 2008, 17:645-654.
10. Buckingham L., Penfield Faber L., Kim A., Liptay M., Barger C., Basu S., Fidler M., Walters K., Bonomi P., Coon J. PTEN, and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int. J. Cancer 2010, 126:1630-1639.
11. Zhang Y.W., Miao Y.F., Yi J., Geng J., Wang R., Chen L.B. Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma 2010, 57:228-233.
12. Lin Q., Geng J., Ma K., Yu J., Sun J., Shen Z., Bao G., Chen Y., Zhang H., He Y., Luo X., Feng X., Zhu J. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J. Cancer Res. Clin. Oncol. 2009, 135:1675-1684.
13. Yanagawa N., Tamura G., Oizumi H., Kanauchi N., Endoh M., Sadahiro M., Motoyama T. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007, 58:131-138.
14. Seng T.J., Currey N., Cooper W.A., Lee C.S., Chan C., Horvath L., Sutherland R.L., Kennedy C., McCaughan B., Kohonen-Corish M.R. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br. J. Cancer 2008, 99:375-382.
15. Yue W., Dacic S., Sun Q., Landreneau R., Guo M., Zhou W., Siegfried J.M., Yu J., Zhang L. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin. Cancer Res. 2007, 13:4336-4344.
16. Fukui T., Kondo M., Ito G., Maeda O., Sato N., Yoshioka H., Yokoi K., Ueda Y., Shimokata K., Sekido Y. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 2005, 24:6323-6327.
17. Kim J.S., Kim J.W., Han J., Shim Y.M., Park J., Kim D.H. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res. 2006, 66:4049-4054.
18. Tsou J.A., Galler J.S., Siegmund K.D., Laird P.W., Turla S., Cozen W., Hagen J.A., Koss M.N., Laird-Offringa I.A. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol. Cancer 2007, 6:70.
19. Furonaka O., Takeshima Y., Awaya H., Ishida H., Kohno N., Inai K K. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol. Int. 2004, 54:549-555.
20. Hsu H.S., Chen T.P., Hung C.H., Wen C.K., Lin R.K., Lee H.C., Wang Y.C. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 2007, 110:2019-2026.
21. Lee M.N., Tseng R.C., Hsu H.S., Chen J.Y., Tzao C., Ho W.L. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 2007, 13:832-838.
22. Wu J.Y., Wang J., Lai J.C., Cheng Y.W., Yeh K.T., Wu T.C., Chen C.Y., Lee H. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Ann. Surg. Oncol. 2008, 15:3272-3277.
23. Irimia M., Fraga M.F., Sanchez-Cespedes M., Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 2004, 23:8695-8699.
24. Waki T., Tamura G., Sato M., Terashima M., Nishizuka S., Motoyama T. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 2003, 94:360-364.
25. Sellar G.C., Watt K.P., Rabiasz G.J., Stronach E.A., Li L., Miller E.P., Massie C.E., Miller J., Contreras-Moreira B., Scott D., Brown I., Williams A.R., Bates P.A., Smyth J.F., Gabra H. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet. 2003, 34:337-343.
26. Wang Y., Li J., Cui Y., Li T., Ng K.M., Geng H., Li H., Shu X.S., Li H., Liu W., Luo B., Zhang Q., Mok T.S., Zheng W., Qiu X., Srivastava G., Yu J., Sung J.J., Chan A.T., Ma D., Tao Q., Han W. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009, 69:5194-5201.
27. Kresse S.H., Ohnstad H.O., Paulsen E.B., Bjerkehagen B., Szuhai K., Serra M., Schaefer K.L., Myklebost O., Meza-Zepeda L.A. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer 2009, 48:679-693.
28. Martin P., Garcia-Cosio M., Santon A., Bellas C. Aberrant gene promoter methylation in plasma cell dyscrasias. Exp. Mol. Pathol. 2008, 84:256-261.
29. Li B., Goyal J., Dhar S., Dimri G., Evron E., Sukumar S., Wazer D.E., Band V. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 2001, 61:8014-8021.
30. Xu X.L., Yu J., Zhang H.Y., Sun M.H., Gu J., Du X., Shi D.R., Wang P., Yang Z.H., Zhu J.D. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J. Gastroenterol. 2004, 10:3441-3454.
31. Yu J., Zhu T., Wang Z., Zhang H., Qian Z., Xu H., Gao B., Wang W., Gu L., Meng J., Wang J., Feng X., Li Y Y., Yao X., Zhu J. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res. 2007, 13:7296-7304.
32. Liu Z., Zhao J., Chen X.F., Li W., Liu R., Lei Z., Liu X., Peng X., Xu K., Chen J., Liu H., Zhou Q.H., Zhang H.T. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Lung Cancer 2008, 62:15-22.
33. Suzuki M., Wada H., Yoshino M., Tian L., Shigematsu H., Suzuki H., Alaa M., Tamura H., Fujiwara T., Nagato K., Motohashi S., Moriya Y., Hoshino H., Yoshida S., Shibuya K., Hiroshima K., Nakatani Y., Yoshino I. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann. Surg. Oncol. 2010, 17:878-888.
34. Razin A., Kantor B. DNA methylation in epigenetic control of gene expression. Prog. Mol. Subcell. Biol. 2005, 38:151-167.
35. Sidiropoulos M., Pampalakis G., Sotiropoulou G., Katsaros D., Diamandis E.P. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 2005, 26:324-336.
36. Huang W., Zhong J., Wu L.Y., Yu L.F., Tian X.L., Zhang X.F., Li B. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett. 2007, 251:78-85.
37. Zhang Y., Song H., Miao Y., Wang R., Chen L. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 2010, 101:934-940.
38. Chen J., Lui W.O., Vos M.D., Clark G.J., Takahashi M., Schoumans J., Khoo S.K., Petillo D., Lavery T., Sugimura J., Astuti D., Zhang C., Kagawa S., Maher E.R., Larsson C., Alberts A.S., Kanayama H.O., Teh B.T. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 2003, 4:405-413.
39. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96:8681-8686.
40. Teodoridis J.M., Hardie C., Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett. 2008, 268:177-186.
41. Marsit C.J., Houseman E.A., Christensen B.C., Eddy K., Bueno R., Sugarbaker D.J., Nelson H.H., Karagas M.R., Kelsey K.T. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res. 2006, 66:10621-10629.
42. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.